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in AML first requires the determination of the individual relapse risk based on diverse chromosomal and molecular 
prognosis-defining aberrations. A broad panel of diagnostic methods is needed to allow such subclassification and pro-
gnostic stratification: cytomorphology, cytogenetics, molecular genetics, and immunophenotyping by multiparameter 
flow cytometry. These methods should not be seen as isolated techniques but as parts of an integral network with hie-
rarchies and interactions. Examples for a poor risk constellation as a clear indication for allogeneic SCT are provided 
by anomalies of chromosome 7, complex aberrations, or FLT3-length mutations. In contrast, the favorable reciprocal 
translocations such as the t(15;17)/PML-RARA or t(8;21)/AML1-ETO are not indications for SCT in first remission 
due to the rather good prognosis after standard therapy. Further, the indication for SCT should include the results of 
minimal residual disease (MRD) diagnostics by polymerase chain reaction (PCR) or flow cytometry. New aspects 
for a safe and fast risk stratification as basis for an optimized indication for SCT in AML might be provided by novel 
technologies such as microarray-based gene expression profiling.
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Introduction
Acute  Myeloid  Leukemia  (AML)  represents  as  highly 
heterogeneous disorder with very variable clinical courses and 
response to chemotherapy. Long term survival ranges from >80% 
in Acute Promyelocytic Leukemia (APL) with the (15;17)/PML-
RARA translocation to <10% in cases with complex aberrations 
(≥3 chromosomal abnormalities). Additionally, the internal tandem 
duplications/length mutations within the FLT3-gene (FLT3-ITD/
LM) confer an extremely adverse prognostic impact (Thiede et 
al, 2002; Schnittger et al, 2002), whereas isolated mutations in 
the Nucleophosmin (NPM1) gene in normal karyotype cases are 
predictive for a more favorable prognosis (Falini et al, 2005).
Due to these variances in outcome, the prospective determination 
of the intensity of treatment in AML is a major task. This applies 
especially to the indications for allogeneic stem cell transplantation 
(SCT), as the benefit of the graft versus leukemia (GvL) effect has 
to be balanced against the risks of transplant-associated morbidity 
and mortality (TRM) in each individual case.
A broad panel of diagnostic methods is necessary to meet the 
demands of an optimized risk stratification which forms basis for 
the decision for SCT: Cytogenetic abnormalities are identified by 
chromosomal banding analyses in ~55% of patients with AML 
and represent the strongest known prognostic parameters in AML 
(Bloomfield et al, 1997; Swansbury et al, 1994). In the remaining 
45%  of  patients  where  no  chromosomal  abnormalities  can  be 
identified, molecular strategies based on diverse polymerase chain 
reaction (PCR) techniques allow a more detailed risk stratification 
in >80% of all cases (Marcucci et al, 2005).
Early  cytomorphological  assessment  of  bone  marrow  blast 
reduction after induction therapy contributes additional prognostic www.ctt-journal.com 2008;1(1)  19
information  (Kern  et  al,  2003a).  This  can  be  combined  with 
multiparameter  flow  cytometry  (MFC),  as  the  quantification 
of cells with a leukemia associated immunophenotype (LAIP) 
before  and  after  induction  therapy  allows  an  early  and  very 
sensitive  evaluation  of  the  response  to  treatment  (Kern  et  al, 
2003b).  Quantitative  PCR  can  also  be  helpful  in  evaluating 
the response to therapy at an early timepoint (Schnittger et al, 
2003). During follow-up of the disease, the quantification of the 
minimal residual disease (MRD) load by PCR and MFC permits 
the detection of impending relapse on a molecular level before 
clinical or morphological manifestation (Grimwade et al, 1996; 
Lo et al, 1999).
Thus, the indication for allogeneic SCT in AML requires not only 
a broad panel of laboratory methods but also has high demands 
for the knowledge and interpretation of a variety of cytogenetic 
and  molecular  markers.  To  further  increase  insights  into  this 
complex panel of criteria that are relevant for the decision for 
allogeneic SCT in AML, this work intends to give an overview of 
the relevant diagnostic methods and markers which can support 
this complex decision process.
Cytomorphological criteria 
The performance of bone marrow cytomorphology shortly after 
the end of induction allows an assessment of early blast clearance 
in AML patients. A reduction of blasts <10% on day 16 after the 
start of induction (“day 16 blasts”) was demonstrated to represent 
a favorable prognostic parameter. In contrast, the persistence of 
higher blast percentages at this time-point is a negative prognostic 
sign and should always provoke the question whether there might 
be an indication for allo-SCT (Preisler et al, 1986; Kern et al, 
2003a).
Cytogenetic criteria
Chromosome banding analyses still play a central role for sub-
classification  and  determination  of  prognosis  in  AML  (Byrd 
et al, 2002; Slovak et al, 2000). To verify the results obtained 
by  chromosome  banding  and  to  further  clarify  more  complex 
aberrations,  several  fluorescence  in  situ  hybridization  (FISH) 
techniques  (e.g.  interphase  FISH,  metaphase  FISH,  24-color 
FISH/SKY) can additionally be performed. Further, interphase 
FISH  provides  a  higher  sensitivity,  as  100-200  cells  can  be 
evaluated without problems in comparison to 20-25 metaphases 
by chromosomal banding (Haferlach et al, 2007).
The  karyotypes  allow  separation  of  AML  patients  into  three 
prognostic  relevant  groups:  The  favorable  subgroup  is 
represented by the recurrent reciprocal translocations t(15;17)/
PML-RARA,  t(8;21)/AML1-ETO,  and  inv(16)/CBFB-MYH11 
from  the  first  hierarchy  of  the  WHO  classification  (Jaffe  et 
al, 2001). Due to the favorable outcome which is achieved by 
standard therapy in these cytogenetic subgroups, allogeneic SCT 
is not performed in first complete remission anymore. However, 
in the case of relapse, allogenic SCT also remains an option in 
these subgroups (de Labarthe et al, 2005; Grimwade et al, 1998; 
Yanada et al, 2005a).
The  second  prognostically  intermediate  subgroup  contains 
patients with a normal karyotype or certain distinct aberrations—
e.g. trisomy 8—which do not confer a specific prognostic impact. 
However, the subgroup of patients with a normal karyotype can be 
separated into several subentities on the basis of diverse molecular 
markers, so the indication for SCT can be further determined and 
differentiated even in this heterogeneous group.
The  third  prognostically  unfavorable  subgroup  includes 
unbalanced karyotypes, characterized by gain or loss of whole 
chromosomes or chromosomal regions. Patients with anomalies 
of chromosomes 3—e.g. an inversion inv(3)/t(3;3)(q21q26)—or 
structural  or  numerical  abnormalities  of  chromosome  7  are 
also part of this group. Complex aberrant karyotypes which 
are defined as >3 chromosomal anomalies are found in 10-15% 
of all AML cases. Conventional chemotherapy achieves stable 




Another  example  are  the  11q23/MLL-rearrangements,  which 
occur often in therapy induced AML (t-AML) after treatment with 
topoisomerase-II inhibitors such as Etoposide.
All these prognostically unfavorable subgroups are characterized 
by  relapse  rates  of  up  to  80%.  Whereas  allogeneic  SCT  was 
shown to result in survival of >40%, intensive chemotherapy or 
high dose chemotherapy followed by autologous stem cell support 
results in long time survival of only 15-20% in these subgroups. 
Therefore, diagnosis of the respective karyotypes should in all 
cases be followed by early planning of allogeneic SCT if possible 
(Suciu et al, 2003).
Previously, it had been thought that secondary AML (s-AML) 
after MDS and therapy associated AML are per se associated 
with  inferior  outcome.  However,  recent  studies  showed  that 
prognostically  unfavorable  karyotypes  are  more  frequent  in 
these subgroups, but that prognosis of the individual karyotypes 
does not differ from the corresponding cytogenetic alterations in 
de novo AML (Messner, 2006; Larson, 2007). However, stable 
disease free survival of >30% has been achieved in s-AML after 
MDS by allogeneic SCT in some studies (de Witte et al, 2000), 
and dose reduced conditioning protocols might further improve 
these results (Kröger et al, 2003).
Molecular criteria
From  molecular  the  aspect,  the  subgroup  of  patients  with  a 
normal karyotype is composed of a large spectrum of diverse 
mutations that are associated with distinct prognostic profiles: 
Length mutations/internal tandem duplications of the FLT3 gene 
(FLT3-LM/ITD), which are represented by insertions of a few 
hundred base pairs, are found in ~40% of all patients with normal 
karyotype (Schnittger et al, 2004;Yanada et al, 2005b). Prognosis 
is  dismal,  and  stable  remissions  after  standard  chemotherapy 
protocols are only seen occasionally (de Labarthe et al, 2005). 
With allogenic SCT, survival could be improved from 20-25% up 
to 45-50% in some studies (Bornhäuser et al, 2007; Schlenk, ASH 
annual meeting abstracts 2006, 108).
In  contrast,  isolated  mutations  of  the  NPM1  gene  are 
prognostically favorable. They are detected in ~50% of all patients 






















Figure 1. Algorithm for the decision process towards allogeneic SCT 
in AML according to the genetic results and to the response to therapy 
„unfavorable“
- complex aberrations 
- chrom. 3 / 7 anomalies 
- 11q23/MLL 
FISH: Fluorescence in situ hybridization; mut.: mutations;
 
MFC: multiparameter flow cytometry; PCR: polymerase chain reaction; 
MRD: minimal residual disease; 









specific association to normal karyotype. The respective mutation 
is represented by diverse subtypes of a 4 base pair insertion and 
results in a disturbed function of a tumor suppressor pathway 
(Falini et al, 2005).
Recently, Schlenk et al. demonstrated that patients with isolated 
NPM1-mutations without evidence of FLT3-length mutations and 
with a normal karyotype do not benefit from allogeneic SCT in 
first remission. However, when the FLT3-LM and the NPM1-
mutation  occur  in  coincidence,  outcome  was  improved  when 
allogeneic SCT was performed (Schlenk, ASH annual meeting 
abstracts 2006, 108).
Other  mutations  are  relevant  as  well,  e.g.  mutations  of  the 
CEPBA-gene.  Due  to  the  favorable  prognosis  their  isolated 
presence should exclude SCT from first-line treatment concepts 
in first remission (Schlenk, ASH annual meeting abstracts 2006, 
108).
The spectrum of molecular markers being able to allow a more 
differentiated indication for SCT in normal karyotype AML is 
continuously increasing: Mutations within the MLL-gene (partial 
tandem duplications, MLL-PTD) are prognostically unfavorable 
(Dohner et al, 2002) and represent a further indication for SCT 
(Schlenk,  ASH  annual  meeting  abstracts  2006,  108).  Thus, 
molecular screening in patients with a normal karyotype is of high 
priority for the decision for SCT. (Table 1 provides an overview 
on the prognostic relevant subgroups in AML on the basis of 
cytogenetic and molecular markers.)
Minimal residual disease criteria
Minimal residual disease (MRD) diagnostics are of increasing 
importance for the definition of therapeutic strategies in AML. 
The highest level of sensitivity (up to 10-5-10
-6) is provided by 
quantitative PCR or nested PCR (Shimoni & Nagler, 2004).
In the reciprocal transcript fusions t(15;17)/PML-RARA, t(8;21)/
AML1-ETO, and inv(16)/CBFB-MYH11 quantitative real-time-
PCR can be used to assess the reduction of the leukemic cell load 
after therapy. A persistence of the transcript (Grimwade et al, 
1998) or a minor decrease (Schnittger et al, 2003) are predictive 
for a significantly enhanced relapse risk. Although these balanced 
translocations play a minor role in SCT nowadays, as patients can 
be cured by standard chemotherapy in many cases, increases of 
the particular molecular markers might be detected 3-6 months 
before the cytomorphological manifestation of relapse and can 
still represent an indication for allogeneic SCT.
So far quantitative PCR is available for part of the known molecular 
mutations  only,  but  efforts  are  being  made  to  develop  such 
quantification strategies for other markers also. In some studies 
of limited size it was shown that the NPM1 mutations represent 
a stable MRD parameter which can be followed quantitatively by 
real-time PCR (Chou et al, 2007; Gorello et al, 2006). For patients 
with the FLT3-LM, follow-up monitoring can be performed by 
semi-quantitative PCR (Schnittger et al, 2004) or by quantitative 
methods  after  design  of  patient-specific  primers  due  to  the 
heterogeneity of the mutations (Scholl et al, 2005b). For some 
markers, e.g. for mutations within the loop of the FLT3 tyrosine 
kinase domain (TKD), assays for quantitative monitoring (Scholl 
et al, 2005a) are being developed, so the spectrum of molecular 
markers being suitable for MRD is continuously expanding.
Another useful method for MRD studies in AML is provided by 
multiparameter flow cytometry (MFC), as a leukemia associated 
immunphenotype (LAIP) can be determined in 95% of all patients 
(Campana, 2003; Kern et al, 2004; Griesinger et al, 1999; Kern et 
al, 2007). Sensitivities of up to 10-2-10-4 are achieved, (Feller et al, 
2004) which also allows MRD monitoring in patients where there 
are no molecular markers for MRD studies available. Numerous 
studies demonstrated that the LAIP positive cells show an increase 
before morphological relapse occurs. Therefore, an increase of 
LAIP  positive  cells  after  therapy  should  always  raise  concern 
and can represent an indication for allogeneic SCT (Laane et al, 
2006). (Figure 1 shows an algorithm for the decision process to 
allogeneic SCT in AML.)
Hierarchy of diagnostic methods
To allow a most efficient flow of methods and an optimized risk 
stratification in the decision process towards allogeneic SCT, the 
diverse methods should be seen in the context of the whole panel, 
and hierarchies between the diverse methods should be used to 
guide the more specific techniques. Cytomorphological results 
raising  suspicion  for  the  balanced  transcripts  t(15;17)/PML-
RARA,  t(8;21)/AML1-ETO,  or  inv(16)/CBFB-MYH11  should 
immediately be followed by the corresponding interphase FISH 
or PCR analyses for confirmation of subtypes.
When  chromosomal  banding  shows  numerical  or  structural 
aberrations,  the  appropriate  interphase  FISH  probes  for 
confirmation and clarification of the results should be selected 
accordingly.  Additionally,  interphase  FISH  can  be  integrated 
in the MRD panel due to the higher sensitivity of 1:100–1:200 
cells (Bacher et al, 2006). In normal karyotype cases, molecular 
screening, e.g., for the NPM1 and FLT3-LM, should be initiated. 
This might be completed by analyses for the CEBPA mutations, 
Table 1. Prognostic subgroups in AML according to the
genetic results









Intermediate  -  Normal karyotype
-  trisomy 8
Unfavorable 
-  complex aberrations  
(≥3 chrom. anomalies)
-  monosomy 7
-  anomalies of chromosome 3 
-  FLT3 length mutations  
(FLT3-LM/FLT3-ITD)
-  MLL-PTD 22  www.ctt-journal.com 2008;1(1)
MLL-PTD, or FLT3-TKD, as these markers all are associated 
with normal karyotype and are essential for risk stratification in 
the indication to SCT (Schlenk et al, 2004). The determination of 
the individual LAIP provides a solid basis for later follow-up to 
detect relapse at the earliest possible timepoint for eventual early 
planning of SCT.
Conclusions
Therapeutic  concepts  in  AML  try  to  adapt  the  intensity  of 
therapy  to  the  individual  relapse  risk.  In  poor-risk  patients, 
allogeneic SCT is the therapy of choice, whereas in patients with 
a good prognosis such as the favorable reciprocal translocations, 
allogeneic SCT is restricted to impending or manifest relapse (de 
Labarthe et al, 2005). This risk stratification is possible only on 
the basis of patient-specific biological parameters and an exact 
subclassification of AML cases according to distinct cytogenetic 
and molecular markers. Further, indications for allogeneic SCT 
should include the results of MRD diagnostics, as persistence or 
increase of molecular markers might be an indication for a change 
of therapy towards SCT.
Thus,  therapeutic  decisions  and  the  indications  for  allogeneic 
SCT require a multimodal diagnostic approach composed by a 
combination of cytogenetics, FISH, molecular genetics, and MRD 
diagnostics based on real time PCR and MFC.
However,  many  questions  still  require  clarification.  The 
combination of diverse markers might be relevant, as prognosis 
might differ from patients with isolated mutations. Examples are 
provided by the coincidence of the PML-RARA mutation with the 
FLT3-LM where prognosis is more unfavorable than in patients 
with an isolated t(15;17) (Gilliland, 2003), or by the coincidence 
of  FLT3-LM  and  NPM1mutations  (Falini  et  al,  2005).  These 
overlaps between the diverse genetic subgroups can be responsible 
for variations in the clinical outcome which are seen in distinct 
AML subentities and need further investigation.
Further,  results  should  be  provided  as  soon  as  possible  after 
diagnosis of AML to pave the way to allogeneic SCT in poor-
risk cases. Novel methods such as gene expression profiling with 
microarrays, which allow the simultaneous analysis of thousands 
of genes, might allow an even more detailed risk stratification 
and prognostication within the shortest time in the near future, 
(Haferlach et al, 2003) which would also facilitate the indication 




In conclusion, an optimized indication for allogeneic SCT in AML 
requires the interaction of a broad panel of diagnostic methods, 
which should be open for new developments to pave the way 
to an easier, safer, and faster risk stratification in this complex 
disorder.
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Оптимизация показаний к аллогенной трансплантации стволовых клеток при 
остром миелобластном лейкозе (ОМЛ), 
основанная на интерактивных диагностических стратегиях
Хартвиг М., Цандер Р.А., Хаферлах Е., Фезе Б., Крегер Н., Бахер У.
Резюме
Показания  к  аллогенной  трансплантации  стволовых  клеток  (алло-ТГСК)  при  остром 
миелобластном  лейкозе  (ОМЛ)  представляют  серьезные  трудности  из-за  клинической  и 
генетической гетерогенности данного заболевания. Поэтому оптимизация показаний к ГАСК при 
ОМЛ требует, прежде всего, определения индивидуального риска рецидива. При этом прогноз 
основывается  на  различных  хромосомных  и  молекулярных  аберрациях.  Необходима  широкая 
панель диагностических приемов, чтобы обеспечить такую субклассификацию и стратификацию 
по  прогнозу,  а  именно:  цитоморфологические,  цитогенетические,  молекулярно-генетические 
методы и иммунофенотипирование посредством мультипарамерической проточной цитометрии. 
Эти методы должны рассматриваться не как изолированные технологии, а как часть интегральной 
сети иерархий и взаимодействий. Неблагоприятным прогностическим маркером считается наличие 
несбалансированных  кариотипов  с  утратой  или  наличием  лишних  хромосом  или  их  крупных 
фрагментов. Приводятся примеры сочетаний маркеров высокого риска для обоснования четких 
показаний к алло-ТГСК, например аномалий хромосомы 7, сложных аберраций (>3 хромосомных 
аномалий)  или  мутаций  по  протяженности  FLT3.  Напротив,  относительно  благоприятные 
реципрокные транслокации, такие, как t(15;17)/PML-RARA или t(8;21)/AML1-ETO и inv(16)/CBFB-
MYH11,  мутации  гена  NPM1.  Не  являются  показанием  к  ТГСК  в  первой  ремиссии,  в  связи  с 
достаточно хорошим прогнозом при проведении стандартной терапии. В дальнейшем показания 
к  ТГСК  должны  включать  в  себя  результаты  оценки  минимальной  остаточной  болезни  (МОБ) 
посредством  полимеразной  цепной  реакции  (ПЦР)  или  проточной  цитометрии.  Новые  аспекты 
безопасной и быстрой стратификации по риску для оптимизации показаний к ТГСК при ОМЛ могут 
быть выработаны на основе новых технологий, таких, как оценка профилей экспрессии множества 
генов с помощью микроэрреев (биочипов). 
Ключевые слова: Острый миелобластный лейкоз (ОМЛ), Аллогенная трансплантация стволовых 
клеток (алло-ТГСК), Показания, Цитогенетика, Полимеразная цепная реакция (ПЦР)
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